EPCAM and carcinoma: EpCAM-ReTARGTPR showed potent in vitro capacity to redirect TPR-specific CD8pos T cells derived from CMV-seropositive/HLA-B*07:02pos individuals to eliminate various types of EpCAM-expressing carcinomas [4].